tiprankstipranks
Trending News
More News >

Erasca Confirms Directors and Ratifies KPMG Appointment

Story Highlights
Erasca Confirms Directors and Ratifies KPMG Appointment

Don’t Miss TipRanks’ Half-Year Sale

Erasca ( (ERAS) ) has issued an announcement.

On June 24, 2025, Erasca, Inc. held its annual meeting of stockholders where two key matters were voted on. The election of three Class I Directors for a three-year term was confirmed, and the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.

The most recent analyst rating on (ERAS) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Erasca stock, see the ERAS Stock Forecast page.

Spark’s Take on ERAS Stock

According to Spark, TipRanks’ AI Analyst, ERAS is a Underperform.

Erasca faces significant financial challenges with no revenue and ongoing losses, which heavily impact its stock score. The technical analysis suggests a potential bearish trend, while the valuation is weak due to persistent losses. These factors collectively indicate a high-risk investment, typical for early-stage biotech firms.

To see Spark’s full report on ERAS stock, click here.

More about Erasca

Erasca, Inc. operates in the biotechnology industry, focusing on developing therapies for cancer treatment.

Average Trading Volume: 1,610,362

Technical Sentiment Signal: Sell

Current Market Cap: $390.9M

Learn more about ERAS stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1